Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Afimoxifene (Primary)
- Indications Early breast cancer; Hyperplasia
- Focus Therapeutic Use
- 24 Apr 2023 Planned End Date changed from 26 Apr 2023 to 26 Oct 2023.
- 24 Apr 2023 Planned primary completion date changed from 26 Apr 2023 to 26 Oct 2023.
- 11 Aug 2022 Planned End Date changed from 26 Oct 2021 to 26 Apr 2023.